An IPO is led by investment banks (underwriters) who price the offer, allocate shares to institutional investors and stabilise the share price post-listing. The Swiss exchange is SIX; Germany uses Xetra/Frankfurt; France, Italy and the Netherlands use Euronext. Notable Swiss IPOs include Galderma (2024) at CHF 53/share with valuation around CHF 12bn, and Sandoz (2023) which spun off from Novartis.
IPOs are statistically poor investments for retail buyers. Academic research (Ritter, Loughran) shows that the average IPO underperforms broad market indices by 20–30% over three years. Reasons: the company sells when valuation is attractive to them (not to you), insiders unload at the lock-up expiry six months later, and the hype usually fades.
Retail investors typically cannot access IPO allocations at the offer price; they buy in the secondary market on day one, often at a 10–30% pop. A more disciplined approach is to wait six months past the lock-up expiry, by which time founder selling has cleared and a normal price discovery has occurred.
Galderma IPO at CHF 53/share in March 2024 raised CHF 2.3bn at a valuation of CHF 12.4bn. Retail investor who buys at first-day close CHF 61 (a 15% pop) and holds for one year: stock trades at CHF 99 — a 62% gain, an unusually successful Swiss IPO.